Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.39 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093713 | 0.92 | PTGS2 (0.44) | PTGS2PTGS1ALOX5MGLLKCNJ6 | |
| SCHEMBL3098825 | 0.90 | PTGS2 (0.42) | PTGS2PTGS1ALOX5MGLLKCNJ6 | |
| SCHEMBL3100407 | 0.90 | PTGS2 (0.50) | PTGS2PTGS1ALOX5MGLLKCNJ6 | |
| SCHEMBL13157631 | 0.89 | PTGS2 (0.48) | KDM1APTGS2PTGS1ALOX5MGLL | |
| SCHEMBL13157561 | 0.89 | PTGS2 (0.42) | PTGS2PTGS1ALOX5MGLLKCNJ6 | |
| SCHEMBL3094206 | 0.88 | MALT1 (0.43) | KDM1APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL3104707 | 0.86 | MGLL (0.54) | PTGS2PTGS1ALOX5MGLLKCNJ6 | |
| SCHEMBL3104741 | 0.86 | CCKAR (0.47) | PTGS2ALOX5 | |
| SCHEMBL3105667 | 0.86 | MGLL (0.54) | PTGS2PTGS1ALOX5MGLLKCNJ6 | |
| SCHEMBL13157564 | 0.86 | PTGS2 (0.43) | PTGS2PTGS1ALOX5MGLLKCNJ6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | KDM1A 3131/4885PTGS2 567/4885PTGS1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.